CRISPR市場：オファリング別、タイプ別、エンドユーザー別、サービス別、用途別、地域別 - 2030年までの予測

世界のCRISPRの市場規模は、2025年の32億1,000万米ドルから2030年には54億7,000万米ドルに達し、CAGRは11.2%と大幅に上昇すると予測されています。

CRISPR市場は大幅な成長を遂げており、研究、臨床、産業用途での採用拡大が顕著なCAGRを牽引しています。この市場拡大には、遺伝性疾患の有病率の上昇、創薬や遺伝子治療におけるCRISPRの利用の拡大、バイオテクノロジー研究開発への投資の増加など、いくつかの要因が寄与しています。加えて、CRISPRツールの進歩、送達システムの改善、規制の整備は、主流研究および治療パイプラインへの統合をさらに加速させます。

オファリング別では、CRISPR市場は製品とサービスの2つの主要セグメントに分類されます。製品セグメントには、CRISPRキット＆酵素、CRISPRライブラリ、その他の製品が含まれます。サービス分野には、gRNA合成と細胞株開発、スクリーニングとバリデーション、その他のサービスが含まれます。

ユーザーは、継続的なイノベーション、新製品のリリース、標準化されたすぐに使えるキットへのアクセスをますます求めるようになっています。これらの製品は、ゲノム編集、機能ゲノミクス、治療開発への応用のため、学術、臨床、産業研究において広く利用されています。これが市場成長を促進する重要な要因です。

用途別セグメントは、創薬＆開発、農業、その他のアプリケーションの3つに分類されます。最大のセグメントは創薬・開発で、CRISPR技術は遺伝子と疾患、薬剤の機能との関連性の同定を容易にすることで初期段階の研究を強化します。このアプローチは、タイムラインを短縮し、成功の可能性を高めるのに役立ちます。さらに、製薬・バイオテクノロジー企業は、個別化医療、遺伝子治療、機能ゲノミクスを推進するため、研究開発プロセスにCRISPRを組み込んでおり、CRISPR技術の活用を強化しています。

エンドユーザー別では、CRISPR製品市場は製薬＆バイオテクノロジー企業、学術＆研究機関、その他のエンドユーザーに区分されます。2024年には、製薬・バイオテクノロジー企業がこの市場を独占します。この優位性は、細胞治療や遺伝子治療への投資の増加、標的同定や検証のための精密な遺伝子ツールの需要によってもたらされています。これらの企業はCRISPR技術に大きく依存しており、その強力な資金力によって高度でカスタマイズされたCRISPR製品を大規模に採用することができ、さらに大きな市場シェアに寄与しています。

市場は地域別に北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカに分けられます。北米はCRISPR市場で最大のシェアを占めており、今後もそのリードを維持すると見られています。この優位性は、著名な研究機関の存在とバイオテクノロジーへの多額の投資に起因します。さらに、米国では最先端の医学研究、個別化医療、精密医療が重視されるようになっており、これが北米に競争上の優位性を与えています。欧州のCRISPR市場も、特にドイツ、英国、フランスなどの国々における研究開発努力の増加に後押しされ、着実な成長を遂げています。

当レポートでは、世界のCRISPR市場について調査し、オファリング別、タイプ別、エンドユーザー別、サービス別、用途別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

• イントロダクション
• 市場力学
• 顧客のビジネスに影響を与える動向/混乱
• サプライチェーン分析
• バリューチェーン分析
• エコシステム分析
• ポーターのファイブフォース分析
• 規制分析
• 価格分析
• 特許分析
• 2025年～2026年の主な会議とイベント
• 主要な利害関係者と購入基準
• 投資と資金調達のシナリオ
• AIがCRISPR市場に与える影響
• 貿易分析

第6章 CRISPR市場、オファリング別

• イントロダクション
• 製品
• サービス

第7章 CRISPR製品市場、タイプ別

• イントロダクション
• CRISPRキットと酵素
• CRISPRライブラリ
• その他

第8章 CRISPR製品市場、エンドユーザー別

• イントロダクション
• 製薬・バイオテクノロジー企業
• 学術研究機関
• その他

第9章 CRISPR市場、サービス別

• イントロダクション
• その他

第10章 CRISPRサービス市場、エンドユーザー別

• イントロダクション
• 製薬・バイオテクノロジー企業
• 学術研究機関
• その他

第11章 CRISPR市場、用途別

• イントロダクション
• 医薬品の発見と開発
• 農業
• その他

第12章 CRISPR市場、地域別

• イントロダクション
• 北米
  • 北米のマクロ経済見通し
  • 米国
  • カナダ
• 欧州
  • 欧州のマクロ経済見通し
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他
• アジア太平洋
  • アジア太平洋のマクロ経済見通し
  • 中国
  • 日本
  • インド
  • その他
• ラテンアメリカ
  • ラテンアメリカのマクロ経済見通し
  • ブラジル
  • その他
• 中東・アフリカ
  • 中東・アフリカのマクロ経済見通し

第13章 競合情勢

• イントロダクション
• 主要参入企業の戦略/強み
• 収益分析、2020年～2024年
• 市場シェア分析、2024年
• 企業評価マトリックス：主要参入企業、2024年
• 企業評価マトリックス：スタートアップ/中小企業、2024年
• 競合シナリオ
• 企業評価と財務指標
• ブランド/製品比較

第14章 企業プロファイル

• 主要参入企業
  • THERMO FISHER SCIENTIFIC INC.
  • MERCK KGAA
  • AGILENT TECHNOLOGIES, INC.
  • GENSCRIPT
  • REVVITY
  • LONZA
  • DANAHER CORPORATION
  • TAKARA BIO INC.
  • CREATIVE BIOGENE
  • FUJIAN SUNYBIOTECH CO., LTD.
  • EDITCO
  • CARIBOU BIOSCIENCES, INC.
  • HERA BIOLABS
  • ORIGENE TECHNOLOGIES, INC.
  • CELLECTA, INC.
• その他の企業
  • MAMMOTH BIOSCIENCES, INC.
  • APPLIED STEMCELL
  • NEW ENGLAND BIOLABS
  • TOOLGEN, INC.
  • GENECOPOEIA, INC.
  • TWIST BIOSCIENCE
  • SYNTHEGO
  • EGENESIS
  • INSCRIPTA, INC.
  • PRECISION BIOSCIENCES

第15章 付録

List of Tables

• TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
• TABLE 2 CRISPR MARKET: RISK ANALYSIS
• TABLE 3 CRISPR MARKET: IMPACT ANALYSIS
• TABLE 4 CRISPR MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• TABLE 5 CRISPR MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 11 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2022-2024
• TABLE 12 AVERAGE SELLING PRICE TREND OF CRISPR KITS AND REAGENTS, BY REGION, 2024 (USD)
• TABLE 13 CRISPR MARKET: INNOVATIONS AND PATENT REGISTRATIONS
• TABLE 14 CRISPR MARKET: KEY CONFERENCES & EVENTS, 2025-2026
• TABLE 15 CRISPR MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
• TABLE 16 IMPORT DATA FOR KITS & REAGENTS, BY REGION, 2019-2023 (USD)
• TABLE 17 EXPORT DATA FOR KITS & REAGENTS, BY REGION, 2019-2023 (USD)
• TABLE 18 US-ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 19 KEY TARIFFS ON PHARMACEUTICAL PRODUCTS
• TABLE 20 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
• TABLE 21 CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 22 CRISPR PRODUCTS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 23 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 24 EUROPE: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 25 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 26 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 27 CRISPR SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 28 NORTH AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 29 EUROPE: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 30 ASIA PACIFIC: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 31 LATIN AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 32 CRISPR PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 33 CRISPR KITS & ENZYMES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 34 NORTH AMERICA: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 35 EUROPE: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 36 ASIA PACIFIC: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 37 LATIN AMERICA: CRISPR KITS & ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 38 CRISPR LIBRARIES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 39 NORTH AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 40 EUROPE: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 41 ASIA PACIFIC: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 42 LATIN AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 43 OTHER CRISPR PRODUCTS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 44 NORTH AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 45 EUROPE: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 46 ASIA PACIFIC: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 47 LATIN AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 48 CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 49 CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 50 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 51 EUROPE: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 52 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 53 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 54 CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 55 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 56 EUROPE: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 57 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 58 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 59 CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 60 NORTH AMERICA: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 61 EUROPE: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 62 ASIA PACIFIC: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 63 LATIN AMERICA: CRISPR PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 64 CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 65 CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY REGION, 2023-2030 (USD MILLION)
• TABLE 66 NORTH AMERICA: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 67 EUROPE: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 68 ASIA PACIFIC: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 69 LATIN AMERICA: CRISPR SERVICES MARKET FOR GRNA SYNTHESIS & CELL LINE DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 70 CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 71 NORTH AMERICA: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 72 EUROPE: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 73 ASIA PACIFIC: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 74 LATIN AMERICA: CRISPR SERVICES MARKET FOR SCREENING & VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 75 OTHER CRISPR SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 76 NORTH AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 77 EUROPE: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 78 ASIA PACIFIC: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 79 LATIN AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 80 CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 81 CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 82 NORTH AMERICA: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 83 EUROPE: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 84 ASIA PACIFIC: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 85 LATIN AMERICA: CRISPR SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 86 CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 87 NORTH AMERICA: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 88 EUROPE: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 89 ASIA PACIFIC: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 90 LATIN AMERICA: CRISPR SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 91 CRISPR SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 92 NORTH AMERICA: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 93 EUROPE: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 94 ASIA PACIFIC: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 95 LATIN AMERICA: CRISPR SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 96 CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 97 CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 98 NORTH AMERICA: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 99 EUROPE: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 100 ASIA PACIFIC: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 101 LATIN AMERICA: CRISPR MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 102 CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 103 NORTH AMERICA: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 104 EUROPE: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 105 ASIA PACIFIC: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 106 LATIN AMERICA: CRISPR MARKET FOR AGRICULTURAL APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 107 CRISPR MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 108 NORTH AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 109 EUROPE: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 110 ASIA PACIFIC: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 111 LATIN AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 112 CRISPR MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 113 NORTH AMERICA: KEY MACROINDICATORS
• TABLE 114 NORTH AMERICA: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 115 NORTH AMERICA: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 116 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 117 NORTH AMERICA: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 118 NORTH AMERICA: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 119 NORTH AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 120 US: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 121 US: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 122 US: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 123 US: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 124 US: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 125 US: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 126 CANADA: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 127 CANADA: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 128 CANADA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 129 CANADA: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 130 CANADA: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 131 CANADA: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 132 EUROPE: KEY MACROINDICATORS
• TABLE 133 EUROPE: CRISPR MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 134 EUROPE: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 135 EUROPE: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 136 EUROPE: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 137 EUROPE: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 138 EUROPE: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 139 EUROPE: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 140 GERMANY: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 141 GERMANY: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 142 GERMANY: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 143 GERMANY: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 144 GERMANY: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 145 GERMANY: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 146 UK: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 147 UK: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 148 UK: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 149 UK: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 150 UK: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 151 UK: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 152 FRANCE: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 153 FRANCE: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 154 FRANCE: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 155 FRANCE: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 156 FRANCE: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 157 FRANCE: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 158 ITALY: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 159 ITALY: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 160 ITALY: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 161 ITALY: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 162 ITALY: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 163 ITALY: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 164 SPAIN: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 165 SPAIN: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 166 SPAIN: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 167 SPAIN: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 168 SPAIN: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 169 SPAIN: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 170 REST OF EUROPE: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 171 REST OF EUROPE: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 172 REST OF EUROPE: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 173 REST OF EUROPE: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 174 REST OF EUROPE: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 175 REST OF EUROPE: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 176 ASIA PACIFIC: KEY MACRO INDICATORS
• TABLE 177 ASIA PACIFIC: CRISPR MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 178 ASIA PACIFIC: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 179 ASIA PACIFIC: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 180 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 181 ASIA PACIFIC: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 182 ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 183 ASIA PACIFIC: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 184 CHINA: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 185 CHINA: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 186 CHINA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 187 CHINA: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 188 CHINA: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 189 CHINA: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 190 JAPAN: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 191 JAPAN: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 192 JAPAN: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 193 JAPAN: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 194 JAPAN: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 195 JAPAN: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 196 INDIA: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 197 INDIA: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 198 INDIA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 199 INDIA: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 200 INDIA: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 201 INDIA: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 202 REST OF ASIA PACIFIC: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 203 REST OF ASIA PACIFIC: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 204 REST OF ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 205 REST OF ASIA PACIFIC: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 206 REST OF ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 207 REST OF ASIA PACIFIC: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 208 LATIN AMERICA: KEY MACROINDICATORS
• TABLE 209 LATIN AMERICA: CRISPR MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 210 LATIN AMERICA: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 211 LATIN AMERICA: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 212 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 213 LATIN AMERICA: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 214 LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 215 LATIN AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 216 BRAZIL: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 217 BRAZIL: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 218 BRAZIL: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 219 BRAZIL: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 220 BRAZIL: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 221 BRAZIL: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 222 REST OF LATIN AMERICA: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 223 REST OF LATIN AMERICA: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 224 REST OF LATIN AMERICA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 225 REST OF LATIN AMERICA: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 226 REST OF LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 227 REST OF LATIN AMERICA: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 228 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
• TABLE 229 MIDDLE EAST & AFRICA: CRISPR MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 230 MIDDLE EAST & AFRICA: CRISPR MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
• TABLE 231 MIDDLE EAST & AFRICA: CRISPR PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 232 MIDDLE EAST & AFRICA: CRISPR MARKET, BY SERVICE, 2023-2030 (USD MILLION)
• TABLE 233 MIDDLE EAST & AFRICA: CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 234 MIDDLE EAST & AFRICA: CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 235 STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET, 2021-2025
• TABLE 236 CRISPR MARKET: DEGREE OF COMPETITION
• TABLE 237 CRISPR MARKET: REGION FOOTPRINT
• TABLE 238 CRISPR MARKET: PRODUCT FOOTPRINT
• TABLE 239 CRISPR MARKET: SERVICE FOOTPRINT
• TABLE 240 CRISPR MARKET: APPLICATION FOOTPRINT
• TABLE 241 CRISPR MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 242 CRISPR MARKET: COMPETITIVE BENCHMARKING OF KEY START UPS/SMES
• TABLE 243 CRISPR MARKET: PRODUCT LAUNCHES, JANUARY 2021-MARCH 2025
• TABLE 244 CRISPR MARKET: DEALS, JANUARY 2021-MARCH 2025
• TABLE 245 CRISPR MARKET: EXPANSIONS, JANUARY 2021-MARCH 2025
• TABLE 246 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• TABLE 247 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
• TABLE 248 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025
• TABLE 249 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-JANUARY 2025
• TABLE 250 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021-JANUARY 2025
• TABLE 251 MERCK KGAA: COMPANY OVERVIEW
• TABLE 252 MERCK KGAA: PRODUCTS/SERVICES OFFERED
• TABLE 253 MERCK KGAA: DEALS, JANUARY 2021-JANUARY 2025
• TABLE 254 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
• TABLE 255 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 256 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021-MARCH 2025
• TABLE 257 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021-MARCH 2025
• TABLE 258 GENSCRIPT: COMPANY OVERVIEW
• TABLE 259 GENSCRIPT: PRODUCTS/SERVICES OFFERED
• TABLE 260 GENSCRIPT: PRODUCT/SERVICE APPROVALS/LAUNCHES, JANUARY 2021-MARCH 2025
• TABLE 261 GENSCRIPT: DEALS, JANUARY 2021-MARCH 2025
• TABLE 262 GENSCRIPT: EXPANSIONS, JANUARY 2021-MARCH 2025
• TABLE 263 REVVITY: COMPANY OVERVIEW
• TABLE 264 REVVITY: PRODUCTS/SERVICES OFFERED
• TABLE 265 REVVITY: DEALS, JANUARY 2021-MARCH 2025
• TABLE 266 LONZA: COMPANY OVERVIEW
• TABLE 267 LONZA: PRODUCTS/SERVICES OFFERED
• TABLE 268 LONZA: DEALS, JANUARY 2021-MARCH 2025
• TABLE 269 DANAHER CORPORATION: COMPANY OVERVIEW
• TABLE 270 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
• TABLE 271 DANAHER CORPORATION: DEALS, JANUARY 2021-MARCH 2025
• TABLE 272 TAKARA BIO INC.: COMPANY OVERVIEW
• TABLE 273 TAKARA BIO INC.: PRODUCTS/SERVICES OFFERED
• TABLE 274 TAKARA BIO INC.: DEALS, JANUARY 2021-MARCH 2025
• TABLE 275 CREATIVE BIOGENE: COMPANY OVERVIEW
• TABLE 276 CREATIVE BIOGENE: PRODUCTS/SERVICES OFFERED
• TABLE 277 CREATIVE BIOGENE: PRODUCT/SERVICE APPROVALS/LAUNCHES, JANUARY 2021-MARCH 2025
• TABLE 278 FUJIAN SUNYBIOTECH CO., LTD.: COMPANY OVERVIEW
• TABLE 279 FUJIAN SUNYBIOTECH CO., LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 280 EDITCO: COMPANY OVERVIEW
• TABLE 281 EDITCO: PRODUCTS/SERVICES OFFERED
• TABLE 282 EDITCO: DEALS, JANUARY 2021-MARCH 2025
• TABLE 283 CARIBOU BIOSCIENCES, INC.: COMPANY OVERVIEW
• TABLE 284 CARIBOU BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 285 CARIBOU BIOSCIENCES, INC.: DEALS, JANUARY 2021-MARCH 2025
• TABLE 286 HERA BIOLABS: COMPANY OVERVIEW
• TABLE 287 HERA BIOLABS: PRODUCTS/SERVICES OFFERED
• TABLE 288 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW
• TABLE 289 ORIGENE TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 290 CELLECTA, INC.: COMPANY OVERVIEW
• TABLE 291 CELLECTA, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 292 MAMMOTH BIOSCIENCES, INC.: COMPANY OVERVIEW
• TABLE 293 APPLIED STEMCELL: COMPANY OVERVIEW
• TABLE 294 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
• TABLE 295 TOOLGEN, INC.: COMPANY OVERVIEW
• TABLE 296 GENECOPOEIA, INC.: COMPANY OVERVIEW
• TABLE 297 TWIST BIOSCIENCE: COMPANY OVERVIEW
• TABLE 298 SYNTHEGO: COMPANY OVERVIEW
• TABLE 299 EGENESIS: COMPANY OVERVIEW
• TABLE 300 INSCRIPTA, INC.: COMPANY OVERVIEW
• TABLE 301 PRECISION BIOSCIENCES: COMPANY OVERVIEW

List of Figures

• FIGURE 1 CRISPR MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 CRISPR MARKET: RESEARCH DESIGN
• FIGURE 3 CRISPR MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
• FIGURE 4 CRISPR MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
• FIGURE 5 CRISPR MARKET ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024
• FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2024)
• FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
• FIGURE 8 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• FIGURE 9 CRISPR MARKET: CAGR PROJECTIONS
• FIGURE 10 DATA TRIANGULATION METHODOLOGY
• FIGURE 11 CRISPR MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
• FIGURE 12 CRISPR MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
• FIGURE 13 CRISPR MARKET: GEOGRAPHICAL SNAPSHOT
• FIGURE 14 RISING FOCUS ON CRISPR THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH
• FIGURE 15 DRUG DISCOVERY & DEVELOPMENT SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2024
• FIGURE 16 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
• FIGURE 17 CRISPR MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 18 TOP 10 LEADING CRISPR STARTUPS BASED ON INVESTMENTS RAISED IN 2024
• FIGURE 19 CRISPR MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 20 CRISPR MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 21 CRISPR MARKET: VALUE CHAIN ANALYSIS
• FIGURE 22 CRISPR MARKET: ECOSYSTEM ANALYSIS
• FIGURE 23 CRISPR MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 24 AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER (2024)
• FIGURE 25 AVERAGE SELLING PRICE OF KITS & REAGENTS, BY REGION, 2024 (USD)
• FIGURE 26 PATENT APPLICATIONS FOR CRISPR (JANUARY 2014-DECEMBER 2024)
• FIGURE 27 CRISPR MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
• FIGURE 28 KEY BUYING CRITERIA OF END USERS FOR CRISPR PRODUCTS
• FIGURE 29 KEY SELECTION CRITERIA OF END USERS FOR CRISPR SERVICES
• FIGURE 30 CRISPR MARKET: INVESTMENT & FUNDING SCENARIO
• FIGURE 31 IMPACT OF AI/GEN AI ON CRISPR MARKET
• FIGURE 32 NORTH AMERICA: CRISPR MARKET SNAPSHOT
• FIGURE 33 ASIA PACIFIC: CRISPR MARKET SNAPSHOT
• FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN CRISPR MARKET, 2020-2024
• FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CRISPR MARKET, 2024
• FIGURE 36 CRISPR MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 37 CRISPR MARKET: COMPANY FOOTPRINT
• FIGURE 38 CRISPR MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
• FIGURE 40 EV/EBITDA OF KEY PLAYERS, 2024
• FIGURE 41 CRISPR MARKET: BRAND/PRODUCT COMPARISON
• FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
• FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2024)
• FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 45 GENSCRIPT: COMPANY SNAPSHOT (2023)
• FIGURE 46 REVVITY: COMPANY SNAPSHOT (2024)
• FIGURE 47 LONZA: COMPANY SNAPSHOT (2024)
• FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
• FIGURE 49 TAKARA BIO INC.: COMPANY SNAPSHOT (2023)
• FIGURE 50 CARIBOU BIOSCIENCES, INC.: COMPANY SNAPSHOT (2024)

The global CRISPR market is anticipated to reach USD 5.47 billion by 2030 from USD 3.21 billion in 2025, at a significant CAGR of 11.2%.

The CRISPR market is experiencing substantial growth, with a notable CAGR driven by its increasing adoption in research, clinical, and industrial applications. Several factors contribute to this market expansion, including the rising prevalence of genetic disorders, the growing use of CRISPR in drug discovery and gene therapy, and increased investments in biotechnology research and development. Additionally, advancements in CRISPR tools, improved delivery systems, and supportive regulatory developments further accelerate its integration into mainstream research and therapeutic pipelines.

"Products dominated the CRISPR market, by offering, in 2024."

Based on offerings, the CRISPR market is categorized into two main segments: products and services. The products segment includes CRISPR kits & enzymes, CRISPR libraries, and other products. The services segment encompasses gRNA synthesis & cell line development, screening & validation, and other services.

Users are increasingly seeking ongoing innovations, new product releases, and access to standardized, ready-to-use kits. These products are widely utilized in academic, clinical, and industrial research for applications in genome editing, functional genomics, and therapeutic development. This is a key factor driving market growth.

"The drug discovery & development application segment is anticipated to grow at a faster pace during the forecast period."

The application segment is divided into three categories: drug discovery & development, agriculture, and other applications. The largest segment is drug discovery & development, as CRISPR technology enhances early-stage research by facilitating the identification of connections between genes and diseases, as well as drug functions. This approach helps reduce timelines and increase the likelihood of success. Additionally, pharmaceutical & biotechnology companies are integrating CRISPR into their research and development processes to advance personalized medicine, gene therapy, and functional genomics, thereby enhancing the utilization of CRISPR technology.

"Pharmaceutical & biotechnology companies dominated the CRISPR products market, by end user, in 2024."

Based on end users, the CRISPR products market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, pharmaceutical & biotechnology companies dominated this market. This dominance is driven by increasing investments in cell and gene therapies, as well as the demand for precise genetic tools for target identification and validation. These companies rely heavily on CRISPR technologies, and their strong financial capacity allows them to adopt advanced and customized CRISPR products at scale, further contributing to their significant market share.

"North America accounted for the largest share of the CRISPR market in 2024."

The market is divided by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest share of the CRISPR market and is expected to maintain its lead. This dominance is attributed to the presence of prominent research institutions and significant investments in biotechnology. Additionally, the growing emphasis on cutting-edge medical research, personalized medicine, and precision medicine in the US gives North America a competitive advantage. The European CRISPR market is also experiencing steady growth, fueled by increased research and development efforts, particularly in countries such as Germany, the UK, and France.

In-depth interviews have been conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the CRISPR market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (35%), Europe (30%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

The prominent players operating in the CRISPR market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Creative Biogene (US), Fujian SunyBiotech Co., Ltd. (China), EditCo (US), Caribou Biosciences, Inc. (US), Lonza Group (Switzerland), Danaher Corporation (US), Revvity, Inc. (US), Hera BioLabs (US), OriGene Technologies, Inc. (US), Cellecta, Inc. (US), Mammoth Biosciences, Inc. (US), Applied StemCell (US), New England Biolabs Inc. (US), ToolGen Inc. (South Korea), GeneCopoeia, Inc. (US), Twist Bioscience Corporation (US), Synthego Corporation (US), eGenesis (US), Inscripta, Inc. (US), and Precision BioSciences, Inc. (US), among others.

Research Coverage:

The CRISPR market report is segmented based on offerings [products (CRISPR kits & enzymes, CRISPR libraries, and other products), services (gRNA synthesis & cell line development, screening & validation, and other services)], applications (drug discovery & development, agriculture, and other applications), and end users [product (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), and service (pharmaceutical & biotechnology companies, academic & research institutes, and other end users)].

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CRISPR market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers new launches, collaborations, acquisitions, and recent developments associated with the CRISPR market.

Key Benefits of Buying the Report:

The report will assist both market leaders and new entrants by providing accurate revenue estimates for CRISPR and its subsegments. It will also help stakeholders better understand the competitive landscape, enabling them to position their businesses effectively and develop suitable go-to-market strategies. Additionally, this report will allow stakeholders to gauge the market dynamics and offer insights into the key drivers, restraints, opportunities, and challenges within the market.

The report provides insights into the following pointers:

• Analysis of key drivers (growing demand for CRISPR-based gene therapies, advancements in CRISPR technology, and growing government and private investments and funding for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccines and treatments for genetic diseases and expanding industrial and agricultural applications of CRISPR), and challenges (regulatory hurdles for CRISPR advancements) influencing the growth of the market.
• Product Development/Innovation: In-depth analysis of emerging technologies in CRISPR, R&D activities, and new product launches in the CRISPR market.
• Market Development: The report provides detailed information about profitable markets and analyzes the market conditions across various regions.
• Market Diversification: Comprehensive information about new products, unexplored regions, recent updates, and investments in the CRISPR market.
• Competitive Assessment: Comprehensive evaluation of market shares, growth strategies, and product & service offerings of leading companies such as Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), and GenScript (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY RESEARCH
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.1.1 Insights From Primary Experts
  • 2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTION
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CRISPR MARKET OVERVIEW
• 4.2 NORTH AMERICA: CRISPR MARKET, BY APPLICATION AND COUNTRY (2024)
• 4.3 CRISPR MARKET SHARE, BY END USER, 2025 VS. 2030

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing demand for CRISPR-based gene therapies
    • 5.2.1.2 Advancements in CRISPR technology
    • 5.2.1.3 Growing government and private investments and funding for CRISPR technology
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Technical challenges associated with CRISPR technology
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Development of new vaccines and treatments for genetic diseases
    • 5.2.3.2 Expanding industrial and agricultural applications of CRISPR
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Regulatory hurdles for CRISPR advancements
  • 5.2.5 TECHNOLOGY ANALYSIS
    • 5.2.5.1 Key technologies
      • 5.2.5.1.1 CRISPR-Cas systems
      • 5.2.5.1.2 gRNA design & optimization
      • 5.2.5.1.3 High-throughput CRISPR screening
    • 5.2.5.2 Complementary technologies
      • 5.2.5.2.1 Synthetic biology
      • 5.2.5.2.2 Single-cell genomics
      • 5.2.5.2.3 Next-generation sequencing
    • 5.2.5.3 Adjacent technologies
      • 5.2.5.3.1 Stem cell engineering
      • 5.2.5.3.2 Synthetic DNA & gene synthesis
      • 5.2.5.3.3 Microfluidics
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 SUPPLY CHAIN ANALYSIS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF BUYERS
  • 5.7.4 BARGAINING POWER OF SUPPLIERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 REGULATORY ANALYSIS
  • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8.2 REGULATORY FRAMEWORK
    • 5.8.2.1 North America
      • 5.8.2.1.1 US
      • 5.8.2.1.2 Canada
    • 5.8.2.2 Europe
      • 5.8.2.2.1 Germany
      • 5.8.2.2.2 UK
      • 5.8.2.2.3 France
    • 5.8.2.3 Asia Pacific
      • 5.8.2.3.1 Japan
      • 5.8.2.3.2 China
    • 5.8.2.4 Latin America
      • 5.8.2.4.1 Brazil
    • 5.8.2.5 Middle East & Africa
      • 5.8.2.5.1 GCC Countries
      • 5.8.2.5.2 South Africa
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER (2024)
  • 5.9.2 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2022-2024
  • 5.9.3 INDICATIVE PRICE TREND FOR CRISPR SERVICES
  • 5.9.4 AVERAGE SELLING PRICE TREND OF CRISPR KITS AND REAGENTS, BY REGION, 2024
• 5.10 PATENT ANALYSIS
• 5.11 KEY CONFERENCES & EVENTS, 2025-2026
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 CRISPR MARKET: BUYING CRITERIA
• 5.13 INVESTMENT & FUNDING SCENARIO
• 5.14 IMPACT OF AI ON CRISPR MARKET
• 5.15 TRADE ANALYSIS
  • 5.15.1 IMPORT DATA FOR KITS & REAGENTS, 2019-2023
  • 5.15.2 EXPORT DATA FOR KITS & REAGENTS, 2019-2023
  • 5.15.3 TRUMP IMPACT OVERVIEW: CRISPR MARKET
    • 5.15.3.1 Introduction
    • 5.15.3.2 Key tariff rates
    • 5.15.3.3 Price impact analysis
    • 5.15.3.4 Key Impact on various regions
      • 5.15.3.4.1 US
      • 5.15.3.4.2 Europe
      • 5.15.3.4.3 Asia Pacific
      • 5.15.3.4.4 Rest of the World
    • 5.15.3.5 End-use industry impact
      • 5.15.3.5.1 Pharmaceutical & biotech companies
      • 5.15.3.5.2 Contract research organizations (CROs)
      • 5.15.3.5.3 Academic & research institutes

6 CRISPR MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 PRODUCTS
  • 6.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
• 6.3 SERVICES
  • 6.3.1 GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET

7 CRISPR PRODUCTS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 CRISPR KITS & ENZYMES
  • 7.2.1 CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD
• 7.3 CRISPR LIBRARIES
  • 7.3.1 INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING TO DRIVE GROWTH
• 7.4 OTHER PRODUCTS

8 CRISPR PRODUCTS MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 8.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET
• 8.3 ACADEMIC & RESEARCH INSTITUTES
  • 8.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
• 8.4 OTHER END USERS

9 CRISPR MARKET, BY SERVICE

• 9.1 INTRODUCTION
  • 9.1.1 GRNA SYNTHESIS & CELL LINE DEVELOPMENT
    • 9.1.1.1 Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth
  • 9.1.2 SCREENING & VALIDATION
    • 9.1.2.1 Rapid advancements in CRISPR technology to drive growth
• 9.2 OTHER SERVICES

10 CRISPR SERVICES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
• 10.3 ACADEMIC & RESEARCH INSTITUTES
  • 10.3.1 INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET
• 10.4 OTHER END USERS

11 CRISPR MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 DRUG DISCOVERY & DEVELOPMENT
  • 11.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
• 11.3 AGRICULTURE
  • 11.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH
• 11.4 OTHER APPLICATIONS

12 CRISPR MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Increasing demand for CRISPR products and services across various industries to drive growth
  • 12.2.3 CANADA
    • 12.2.3.1 Increasing demand for gene-editing technologies to boost growth
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK OF EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Rapidly increasing biotechnology sector to support growth
  • 12.3.3 UK
    • 12.3.3.1 Significant government investments in genomics research to propel growth
  • 12.3.4 FRANCE
    • 12.3.4.1 Increasing demand for targeted therapies and personalized medicine to propel growth
  • 12.3.5 ITALY
    • 12.3.5.1 Increasing demand for innovative therapeutic solutions to drive growth
  • 12.3.6 SPAIN
    • 12.3.6.1 Increasing demand for precision medicine to drive growth
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Increasing investments in R&D to drive growth
  • 12.4.3 JAPAN
    • 12.4.3.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth
  • 12.4.4 INDIA
    • 12.4.4.1 Increasing prevalence of genetic disorders to support growth
  • 12.4.5 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Growing adoption of genome technologies to propel growth
  • 12.5.3 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET
• 13.3 REVENUE ANALYSIS, 2020-2024
• 13.4 MARKET SHARE ANALYSIS, 2024
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Region footprint
    • 13.5.5.3 Product footprint
    • 13.5.5.4 Service footprint
    • 13.5.5.5 Application footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
    • 13.6.5.1 Detailed list of key startups/SMEs
    • 13.6.5.2 Competitive benchmarking of key startups/SMEs
• 13.7 COMPETITIVE SCENARIO
  • 13.7.1 PRODUCT LAUNCHES & APPROVALS
  • 13.7.2 DEALS
  • 13.7.3 EXPANSIONS
• 13.8 COMPANY VALUATION & FINANCIAL METRICS
• 13.9 BRAND/PRODUCT COMPARISON

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 THERMO FISHER SCIENTIFIC INC.
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products/Services offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product/Service launches
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 MERCK KGAA
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products/Services offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Deals
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses & competitive threats
  • 14.1.3 AGILENT TECHNOLOGIES, INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products/Services offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Deals
      • 14.1.3.3.2 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses & competitive threats
  • 14.1.4 GENSCRIPT
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products/Services offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product/service approvals/launches
      • 14.1.4.3.2 Deals
      • 14.1.4.3.3 Expansions
  • 14.1.5 REVVITY
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products/Services offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Deals
  • 14.1.6 LONZA
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products/Services offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Deals
  • 14.1.7 DANAHER CORPORATION
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products/Services offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Deals
  • 14.1.8 TAKARA BIO INC.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products/Services offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
  • 14.1.9 CREATIVE BIOGENE
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products/Services offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Product/service approvals/launches
  • 14.1.10 FUJIAN SUNYBIOTECH CO., LTD.
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products/Services offered
  • 14.1.11 EDITCO
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products/Services offered
    • 14.1.11.3 Recent financials
      • 14.1.11.3.1 Deals
  • 14.1.12 CARIBOU BIOSCIENCES, INC.
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products/Services offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Deals
  • 14.1.13 HERA BIOLABS
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products/Services offered
  • 14.1.14 ORIGENE TECHNOLOGIES, INC.
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products/Services offered
  • 14.1.15 CELLECTA, INC.
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products/Services offered
• 14.2 OTHER PLAYERS
  • 14.2.1 MAMMOTH BIOSCIENCES, INC.
  • 14.2.2 APPLIED STEMCELL
  • 14.2.3 NEW ENGLAND BIOLABS
  • 14.2.4 TOOLGEN, INC.
  • 14.2.5 GENECOPOEIA, INC.
  • 14.2.6 TWIST BIOSCIENCE
  • 14.2.7 SYNTHEGO
  • 14.2.8 EGENESIS
  • 14.2.9 INSCRIPTA, INC.
  • 14.2.10 PRECISION BIOSCIENCES

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS